nach oben

02.11.2023 | Original Article

Effects of Dapagliflozin on Myocardial Gene Expression in BTBR Mice with Type 2 Diabetes

verfasst von: Maria Ryaboshapkina, Regina Ye, Yumei Ye, Yochai Birnbaum

Erschienen in: Cardiovascular Drugs and Therapy

Einloggen, um Zugang zu erhalten

Abstract

Background

Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, is approved for the treatment of type 2 diabetes, heart failure, and chronic kidney disease. DAPA-HF and DELIVER trial results demonstrate that the cardiovascular protective effect of dapagliflozin extends to non-diabetic patients. Hence, the mechanism-of-action may extend beyond glucose-lowering and is not completely elucidated. We have previously shown that dapagliflozin reduces cardiac hypertrophy, inflammation, fibrosis, and apoptosis and increases ejection fraction in BTBR mice with type 2 diabetes.

Methods

We conducted a follow-up RNA-sequencing study on the heart tissue of these animals and performed differential expression and Ingenuity Pathway analysis. Selected markers were confirmed by RT-PCR and Western blot.

Results

SGLT2 had negligible expression in heart tissue. Dapagliflozin improved cardiac metabolism by decreasing glycolysis and pyruvate utilization enzymes, induced antioxidant enzymes, and decreased expression of hypoxia markers. Expression of inflammation, apoptosis, and hypertrophy pathways was decreased. These observations corresponded to the effects of dapagliflozin in the clinical trials.

Nur mit Berechtigung zugänglich

Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57. https://doi.org/10.1056/NEJMoa1812389.CrossRefPubMed

Cefalu WT, Kaul S, Gerstein HC, et al. Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a diabetes care editors' expert forum. Diabetes Care. 2018;41(1):14–31. https://doi.org/10.2337/dci17-0057.CrossRefPubMed

McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. https://doi.org/10.1056/NEJMoa1911303.CrossRefPubMed

Inzucchi SE, Claggett BL, Vaduganathan M, et al. Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2022;10(12):869–81. https://doi.org/10.1016/S2213-8587(22)00308-4.CrossRefPubMed

Joubert M, Jagu B, Montaigne D, et al. The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model. Diabetes. 2017;66(4):1030–40. https://doi.org/10.2337/db16-0733.CrossRefPubMed

Arow M, Waldman M, Yadin D, et al. Sodium-glucose cotransporter 2 inhibitor dapagliflozin attenuates diabetic cardiomyopathy. Cardiovasc Diabetol. 2020;19(1):7. https://doi.org/10.1186/s12933-019-0980-4.CrossRefPubMedPubMedCentral

Saleh S, Hanna G, El-Nabi SH, et al. Dapagliflozin, a sodium glucose cotransporter 2 inhibitors, protects cardiovascular function in type-2 diabetic murine model. J Genet. 2020;99:1–8. https://doi.org/10.1007/s12041-020-01196-9.CrossRef

Olgar Y, Turan B. A sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin comparison with insulin shows important effects on Zn(2+)-transporters in cardiomyocytes from insulin-resistant metabolic syndrome rats through inhibition of oxidative stress. Can J Physiol Pharmacol. 2019;97(6):528–35. https://doi.org/10.1139/cjpp-2018-0466.CrossRefPubMed

Shi L, Zhu D, Wang S, Jiang A, Li F. Dapagliflozin attenuates cardiac remodeling in mice model of cardiac pressure overload. Am J Hypertens. 2019;32(5):452–9. https://doi.org/10.1093/ajh/hpz016.CrossRefPubMed

10.

Ye Y, Bajaj M, Yang HC, Perez-Polo JR, Birnbaum Y. SGLT-2 Inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor. Cardiovasc Drugs Ther. 2017;31(2):119–32. https://doi.org/10.1007/s10557-017-6725-2.CrossRefPubMed

11.

Chen H, Tran D, Yang HC, et al. Dapagliflozin and ticagrelor have additive effects on the attenuation of the activation of the NLRP3 inflammasome and the progression of diabetic cardiomyopathy: an AMPK-mTOR interplay. Cardiovasc Drugs Ther. 2020;34(4):443–61. https://doi.org/10.1007/s10557-020-06978-y.CrossRefPubMed

12.

Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15–21. https://doi.org/10.1093/bioinformatics/bts635.CrossRefPubMed

13.

Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. https://doi.org/10.1186/s13059-014-0550-8.CrossRefPubMedPubMedCentral

14.

Wickham H. ggplot2: elegant graphics for data analysis. New York: Springer; 2016.CrossRef

15.

Mak TW, Hauck L, Grothe D, Billia F. p53 regulates the cardiac transcriptome. Proc Natl Acad Sci USA. 2017;114(9):2331–6. https://doi.org/10.1073/pnas.1621436114.CrossRefPubMedPubMedCentral

16.

Croteau D, Luptak I, Chambers JM, et al. Effects of sodium-glucose linked transporter 2 inhibition with ertugliflozin on mitochondrial function, energetics, and metabolic gene expression in the presence and absence of diabetes mellitus in mice. J Am Heart Assoc. 2021;10(13):e019995. https://doi.org/10.1161/JAHA.120.019995.CrossRefPubMedPubMedCentral

17.

Zhang S, Liu H, Amarsingh GV, et al. Diabetic cardiomyopathy is associated with defective myocellular copper regulation and both defects are rectified by divalent copper chelation. Cardiovasc Diabetol. 2014;13:100. https://doi.org/10.1186/1475-2840-13-100.CrossRefPubMedPubMedCentral

18.

Uthman L, Kuschma M, Romer G, et al. Novel anti-inflammatory effects of canagliflozin involving hexokinase II in lipopolysaccharide-stimulated human coronary artery endothelial cells. Cardiovasc Drugs Ther. 2021;35(6):1083–94. https://doi.org/10.1007/s10557-020-07083-w.CrossRefPubMed

19.

Nair V, Schaub J, Alakwaa F, et al. WCN23-0761 SGLT2 inhibitor treatment may enhance kidney oxygenation and attenuate HIF1a expression in young persons with type 2 diabetes. Kindney Int Rep. 2023;8(3):S197–S8. https://doi.org/10.1016/j.ekir.2023.02.439.CrossRef

20.

Nagatomo Y, Meguro T, Ito H, et al. Significance of AT1 receptor independent activation of mineralocorticoid receptor in murine diabetic cardiomyopathy. PLoS One. 2014;9(3):e93145. https://doi.org/10.1371/journal.pone.0093145.CrossRefPubMedPubMedCentral

21.

Chao PC, Hsu CC, Yin MC. Anti-inflammatory and anti-coagulatory activities of caffeic acid and ellagic acid in cardiac tissue of diabetic mice. Nutr Metab (Lond). 2009;6:33. https://doi.org/10.1186/1743-7075-6-33.CrossRefPubMedPubMedCentral

22.

Mushtaq I, Bashir Z, Sarwar M, et al. N-acetyl cysteine, selenium, and ascorbic acid rescue diabetic cardiac hypertrophy via mitochondrial-associated redox regulators. Molecules. 2021;26(23) https://doi.org/10.3390/molecules26237285.

23.

Kain V, Kumar S, Sitasawad SL. Azelnidipine prevents cardiac dysfunction in streptozotocin-diabetic rats by reducing intracellular calcium accumulation, oxidative stress and apoptosis. Cardiovasc Diabetol. 2011;10:97. https://doi.org/10.1186/1475-2840-10-97.CrossRefPubMedPubMedCentral

24.

Ding W, Chang WG, Guo XC, et al. Exenatide protects against cardiac dysfunction by attenuating oxidative stress in the diabetic mouse heart. Front Endocrinol (Lausanne). 2019;10:202. https://doi.org/10.3389/fendo.2019.00202.CrossRefPubMedPubMedCentral

25.

Cotrin JC, de Souza GSM, Petito-da-Silva TI, et al. Empagliflozin alleviates left ventricle hypertrophy in high-fat-fed mice by modulating renin angiotensin pathway. J Renin Angiotensin Aldosterone Syst. 2022;2022:8861911. https://doi.org/10.1155/2022/8861911.CrossRefPubMedPubMedCentral

26.

Oshima H, Miki T, Kuno A, et al. Empagliflozin, an SGLT2 inhibitor, reduced the mortality rate after acute myocardial infarction with modification of cardiac metabolomes and antioxidants in diabetic rats. J Pharmacol Exp Ther. 2019;368(3):524–34. https://doi.org/10.1124/jpet.118.253666.CrossRefPubMed

27.

Nabrdalik-Lesniak D, Nabrdalik K, Sedlaczek K, et al. Influence of SGLT2 inhibitor treatment on urine antioxidant status in type 2 diabetic patients: a pilot study. Oxid Med Cell Longev. 2021;2021:5593589. https://doi.org/10.1155/2021/5593589.CrossRefPubMedPubMedCentral

28.

Xue W, Liu Y, Zhao J, et al. Activation of HIF-1 by metallothionein contributes to cardiac protection in the diabetic heart. Am J Physiol Heart Circ Physiol. 2012;302(12):H2528–35. https://doi.org/10.1152/ajpheart.00850.2011.CrossRefPubMed

29.

Kim S, Jo CH, Kim GH. Effects of empagliflozin on nondiabetic salt-sensitive hypertension in uninephrectomized rats. Hypertens Res. 2019;42(12):1905–15. https://doi.org/10.1038/s41440-019-0326-3.CrossRefPubMedPubMedCentral

30.

Bessho R, Takiyama Y, Takiyama T, et al. Hypoxia-inducible factor-1alpha is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy. Sci Rep. 2019;9(1):14754. https://doi.org/10.1038/s41598-019-51343-1.CrossRefPubMedPubMedCentral

31.

Ghanim H, Abuaysheh S, Hejna J, et al. Dapagliflozin suppresses hepcidin and increases erythropoiesis. J Clin Endocrinol Metab. 2020;105(4) https://doi.org/10.1210/clinem/dgaa057.

32.

Peake BF, Nicholson CK, Lambert JP, et al. Hydrogen sulfide preconditions the db/db diabetic mouse heart against ischemia-reperfusion injury by activating Nrf2 signaling in an Erk-dependent manner. Am J Physiol Heart Circ Physiol. 2013;304(9):H1215–24. https://doi.org/10.1152/ajpheart.00796.2012.CrossRefPubMedPubMedCentral

33.

Li C, Zhang J, Xue M, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol. 2019;18(1):15. https://doi.org/10.1186/s12933-019-0816-2.CrossRefPubMedPubMedCentral

34.

Xia Y, Gong L, Liu H, et al. Inhibition of prolyl hydroxylase 3 ameliorates cardiac dysfunction in diabetic cardiomyopathy. Mol Cell Endocrinol. 2015;403:21–9. https://doi.org/10.1016/j.mce.2015.01.014.CrossRefPubMed

35.

Han B, Baliga R, Huang H, Giannone PJ, Bauer JA. Decreased cardiac expression of vascular endothelial growth factor and redox imbalance in murine diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol. 2009;297(2):H829–35. https://doi.org/10.1152/ajpheart.00222.2009.CrossRefPubMed

36.

Gui C, Zeng ZY, Chen Q, et al. Neuregulin-1 promotes myocardial angiogenesis in the rat model of diabetic cardiomyopathy. Cell Physiol Biochem. 2018;46(6):2325–34. https://doi.org/10.1159/000489622.CrossRefPubMed

37.

Zhang WY, Wang J, Li AZ. A study of the effects of SGLT-2 inhibitors on diabetic cardiomyopathy through miR-30d/KLF9/VEGFA pathway. Eur Rev Med Pharmacol Sci. 2020;24(11):6346–59. https://doi.org/10.26355/eurrev_202006_21533.CrossRefPubMed

38.

Wang M, Lv Q, Zhao L, et al. Metoprolol and bisoprolol ameliorate hypertrophy of neonatal rat cardiomyocytes induced by high glucose via the PKC/NF-kappaB/c-fos signaling pathway. Exp Ther Med. 2020;19(2):871–82. https://doi.org/10.3892/etm.2019.8312.CrossRefPubMed

39.

Nguyen T, Wen S, Gong M, et al. Dapagliflozin activates neurons in the central nervous system and regulates cardiovascular activity by inhibiting SGLT-2 in mice. Diabetes Metab Syndr Obes. 2020;13:2781–99. https://doi.org/10.2147/DMSO.S258593.CrossRefPubMedPubMedCentral

40.

Raut SK, Singh GB, Rastogi B, et al. miR-30c and miR-181a synergistically modulate p53-p21 pathway in diabetes induced cardiac hypertrophy. Mol Cell Biochem. 2016;417(1-2):191–203. https://doi.org/10.1007/s11010-016-2729-7.CrossRefPubMed

41.

Cheng Y, Li J, Wang C, et al. Inhibition of long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 attenuates high glucose-induced cardiomyocyte apoptosis via regulation of miR-181a-5p. Exp Anim. 2020;69(1):34–44. https://doi.org/10.1538/expanim.19-0058.CrossRefPubMed

42.

Kim MN, Moon JH, Cho YM. Sodium-glucose cotransporter-2 inhibition reduces cellular senescence in the diabetic kidney by promoting ketone body-induced NRF2 activation. Diabetes Obes Metab. 2021;23(11):2561–71. https://doi.org/10.1111/dom.14503.CrossRefPubMed

43.

Park SH, Farooq MA, Gaertner S, et al. Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat. Cardiovasc Diabetol. 2020;19(1):19. https://doi.org/10.1186/s12933-020-00997-7.CrossRefPubMedPubMedCentral

44.

Van Linthout S, Seeland U, Riad A, et al. Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol. 2008;103(4):319–27. https://doi.org/10.1007/s00395-008-0715-2.CrossRefPubMed

45.

Wang SQ, Li D, Yuan Y. Long-term moderate intensity exercise alleviates myocardial fibrosis in type 2 diabetic rats via inhibitions of oxidative stress and TGF-beta1/Smad pathway. J Physiol Sci. 2019;69(6):861–73. https://doi.org/10.1007/s12576-019-00696-3.CrossRefPubMed

46.

Talior-Volodarsky I, Connelly KA, Arora PD, Gullberg D, McCulloch CA. alpha11 integrin stimulates myofibroblast differentiation in diabetic cardiomyopathy. Cardiovasc Res. 2012;96(2):265–75. https://doi.org/10.1093/cvr/cvs259.CrossRefPubMed

47.

Pan X, Phanish MK, Baines DL, Dockrell MEC. High glucose-induced Smad3 linker phosphorylation and CCN2 expression are inhibited by dapagliflozin in a diabetic tubule epithelial cell model. Biosci Rep. 2021;41(6) https://doi.org/10.1042/BSR20203947.

48.

Xiao T, Zeng O, Luo J, et al. Effects of hydrogen sulfide on myocardial fibrosis in diabetic rats: changes in matrix metalloproteinases parameters. Biomed Mater Eng. 2015;26(Suppl 1):S2033–9. https://doi.org/10.3233/BME-151508.CrossRefPubMed

49.

Dede E, Liapis D, Davos C, et al. The effects of exercise training on cardiac matrix metalloproteinases activity and cardiac function in mice with diabetic cardiomyopathy. Biochem Biophys Res Commun. 2022;586:8–13. https://doi.org/10.1016/j.bbrc.2021.11.013.CrossRefPubMed

50.

Dawood AF, Alzamil NM, Hewett PW, et al. Metformin protects against diabetic cardiomyopathy: an association between Desmin-Sarcomere injury and the iNOS/mTOR/TIMP-1 fibrosis axis. Biomedicines. 2022;10(5) https://doi.org/10.3390/biomedicines10050984.

51.

Meng L, Uzui H, Guo H, Tada H. Role of SGLT1 in high glucose level-induced MMP-2 expression in human cardiac fibroblasts. Mol Med Rep. 2018;17(5):6887–92. https://doi.org/10.3892/mmr.2018.8688.CrossRefPubMed

52.

Li W, Lou X, Zha Y, et al. Single-cell RNA-seq of heart reveals intercellular communication drivers of myocardial fibrosis in diabetic cardiomyopathy. Elife. 2023:12. https://doi.org/10.7554/eLife.80479.

53.

Saucedo-Orozco H, Voorrips SN, Yurista SR, de Boer RA, Westenbrink BD. SGLT2 Inhibitors and ketone metabolism in heart failure. J Lipid Atheroscler. 2022;11(1):1–19. https://doi.org/10.12997/jla.2022.11.1.1.CrossRefPubMedPubMedCentral

54.

Chen S, Coronel R, Hollmann MW, Weber NC, Zuurbier CJ. Direct cardiac effects of SGLT2 inhibitors. Cardiovasc Diabetol. 2022;21(1):45. https://doi.org/10.1186/s12933-022-01480-1.CrossRefPubMedPubMedCentral

55.

Da Silva D, Ausina P, Alencar EM, et al. Metformin reverses hexokinase and phosphofructokinase downregulation and intracellular distribution in the heart of diabetic mice. IUBMB Life. 2012;64(9):766–74. https://doi.org/10.1002/iub.1063.CrossRefPubMed

56.

Sousa Fialho MDL, Purnama U, Dennis K, et al. Activation of HIF1alpha rescues the hypoxic response and reverses metabolic dysfunction in the diabetic heart. Diabetes. 2021;70(11):2518–31. https://doi.org/10.2337/db21-0398.CrossRefPubMedPubMedCentral

57.

Byrne NJ, Rajasekaran NS, Abel ED, Bugger H. Therapeutic potential of targeting oxidative stress in diabetic cardiomyopathy. Free Radic Biol Med. 2021;169:317–42. https://doi.org/10.1016/j.freeradbiomed.2021.03.046.CrossRefPubMedPubMedCentral

58.

Sha W, Hu F, Xi Y, Chu Y, Bu S. Mechanism of ferroptosis and its role in type 2 diabetes mellitus. J Diabetes Res. 2021;2021:9999612. https://doi.org/10.1155/2021/9999612.CrossRefPubMedPubMedCentral

59.

Katunga LA, Gudimella P, Efird JT, et al. Obesity in a model of gpx4 haploinsufficiency uncovers a causal role for lipid-derived aldehydes in human metabolic disease and cardiomyopathy. Mol Metab. 2015;4(6):493–506. https://doi.org/10.1016/j.molmet.2015.04.001.CrossRefPubMedPubMedCentral

60.

Baseler WA, Dabkowski ER, Jagannathan R, et al. Reversal of mitochondrial proteomic loss in type 1 diabetic heart with overexpression of phospholipid hydroperoxide glutathione peroxidase. Am J Physiol Regul Integr Comp Physiol. 2013;304(7):R553–65. https://doi.org/10.1152/ajpregu.00249.2012.CrossRefPubMedPubMedCentral

61.

Feng W, Wang Y, Cai L, Kang YJ. Metallothionein rescues hypoxia-inducible factor-1 transcriptional activity in cardiomyocytes under diabetic conditions. Biochem Biophys Res Commun. 2007;360(1):286–9. https://doi.org/10.1016/j.bbrc.2007.06.057.CrossRefPubMedPubMedCentral

62.

Huang S, Wang J, Men H, et al. Cardiac metallothionein overexpression rescues diabetic cardiomyopathy in Akt2-knockout mice. J Cell Mol Med. 2021;25(14):6828–40. https://doi.org/10.1111/jcmm.16687.CrossRefPubMedPubMedCentral

63.

Gu J, Yan X, Dai X, et al. Metallothionein preserves Akt2 activity and cardiac function via inhibiting TRB3 in diabetic hearts. Diabetes. 2018;67(3):507–17. https://doi.org/10.2337/db17-0219.CrossRefPubMed

64.

Gu J, Cheng Y, Wu H, et al. Metallothionein is downstream of Nrf2 and partially mediates sulforaphane prevention of diabetic cardiomyopathy. Diabetes. 2017;66(2):529–42. https://doi.org/10.2337/db15-1274.CrossRefPubMed

65.

Kobylecki CJ, Afzal S, Nordestgaard BG. Genetically low antioxidant protection and risk of cardiovascular disease and heart failure in diabetic subjects. EBioMedicine. 2015;2(12):2010–5. https://doi.org/10.1016/j.ebiom.2015.11.026.CrossRefPubMedPubMedCentral

66.

Gao YH, Li CX, Shen SM, et al. Hypoxia-inducible factor 1alpha mediates the down-regulation of superoxide dismutase 2 in von Hippel-Lindau deficient renal clear cell carcinoma. Biochem Biophys Res Commun. 2013;435(1):46–51. https://doi.org/10.1016/j.bbrc.2013.04.034.CrossRefPubMed

67.

Bohuslavova R, Kolar F, Sedmera D, et al. Partial deficiency of HIF-1alpha stimulates pathological cardiac changes in streptozotocin-induced diabetic mice. BMC Endocr Disord. 2014;14:11. https://doi.org/10.1186/1472-6823-14-11.CrossRefPubMedPubMedCentral

68.

Gao Q, Guan L, Hu S, et al. Study on the mechanism of HIF1a-SOX9 in glucose-induced cardiomyocyte hypertrophy. Biomed Pharmacother. 2015;74:57–62. https://doi.org/10.1016/j.biopha.2015.07.009.CrossRefPubMed

69.

Huang YT, Liu CH, Yang YC, et al. ROS- and HIF1alpha-dependent IGFBP3 upregulation blocks IGF1 survival signaling and thereby mediates high-glucose-induced cardiomyocyte apoptosis. J Cell Physiol. 2019;234(8):13557–70. https://doi.org/10.1002/jcp.28034.CrossRefPubMed

70.

Packer M. Mechanisms leading to differential hypoxia-inducible factor signaling in the diabetic kidney: modulation by SGLT2 inhibitors and hypoxia mimetics. Am J Kidney Dis. 2021;77(2):280–6. https://doi.org/10.1053/j.ajkd.2020.04.016.CrossRefPubMed

71.

Kondo K, Ishigaki Y, Gao J, et al. Bach1 deficiency protects pancreatic beta-cells from oxidative stress injury. Am J Physiol Endocrinol Metab. 2013;305(5):E641–8. https://doi.org/10.1152/ajpendo.00120.2013.CrossRefPubMed

72.

Yan B, Jiao S, Zhang HS, et al. Prolyl hydroxylase domain protein 3 targets Pax2 for destruction. Biochem Biophys Res Commun. 2011;409(2):315–20. https://doi.org/10.1016/j.bbrc.2011.05.012.CrossRefPubMed

73.

Li CL, Liu B, Wang ZY, et al. Salvianolic acid B improves myocardial function in diabetic cardiomyopathy by suppressing IGFBP3. J Mol Cell Cardiol. 2020;139:98–112. https://doi.org/10.1016/j.yjmcc.2020.01.009.CrossRefPubMed

74.

Lai J, Chen F, Chen J, et al. Overexpression of decorin promoted angiogenesis in diabetic cardiomyopathy via IGF1R-AKT-VEGF signaling. Sci Rep. 2017;7:44473. https://doi.org/10.1038/srep44473.CrossRefPubMedPubMedCentral

75.

Ramakrishnan S, Anand V, Roy S. Vascular endothelial growth factor signaling in hypoxia and inflammation. J Neuroimmune Pharmacol. 2014;9(2):142–60. https://doi.org/10.1007/s11481-014-9531-7.CrossRefPubMedPubMedCentral

76.

Lu H, Fedak PW, Dai X, et al. Integrin-linked kinase expression is elevated in human cardiac hypertrophy and induces hypertrophy in transgenic mice. Circulation. 2006;114(21):2271–9. https://doi.org/10.1161/CIRCULATIONAHA.106.642330.CrossRefPubMed

77.

Wicik Z, Nowak A, Jarosz-Popek J, et al. Characterization of the SGLT2 interaction network and its regulation by SGLT2 inhibitors: a bioinformatic analysis. Front Pharmacol. 2022;13:901340. https://doi.org/10.3389/fphar.2022.901340.CrossRefPubMedPubMedCentral

78.

Gupte M, Umbarkar P, Lal H. Mechanistic insights of empagliflozin-mediated cardiac benefits: nearing the starting line : editorial to: "Empagliflozin improves left ventricular diastolic dysfunction in a genetic model of type 2 diabetes" by N. Hammoudi et al. Cardiovasc Drugs Ther. 2017;31(3):229–32. https://doi.org/10.1007/s10557-017-6741-2.CrossRefPubMed

79.

Min W, Bin ZW, Quan ZB, Hui ZJ, Sheng FG. The signal transduction pathway of PKC/NF-kappa B/c-fos may be involved in the influence of high glucose on the cardiomyocytes of neonatal rats. Cardiovasc Diabetol. 2009;8:8. https://doi.org/10.1186/1475-2840-8-8.CrossRefPubMedPubMedCentral

80.

Wang M, Zhang WB, Zhu JH, Fu GS, Zhou BQ. Breviscapine ameliorates hypertrophy of cardiomyocytes induced by high glucose in diabetic rats via the PKC signaling pathway. Acta Pharmacol Sin. 2009;30(8):1081–91. https://doi.org/10.1038/aps.2009.95.CrossRefPubMedPubMedCentral

81.

Radovits T, Korkmaz S, Matyas C, et al. An altered pattern of myocardial histopathological and molecular changes underlies the different characteristics of type-1 and type-2 diabetic cardiac dysfunction. J Diabetes Res. 2015;2015:728741. https://doi.org/10.1155/2015/728741.CrossRefPubMedPubMedCentral

82.

Oh CC, Lee J, D'Souza K, et al. Activator protein-1 and caspase 8 mediate p38alpha MAPK-dependent cardiomyocyte apoptosis induced by palmitic acid. Apoptosis. 2019;24(5-6):395–403. https://doi.org/10.1007/s10495-018-01510-y.CrossRefPubMed

83.

Zhu N, Huang B, Zhu L, Wang Y. Potential mechanisms of triptolide against diabetic cardiomyopathy based on network pharmacology analysis and molecular docking. J Diabetes Res. 2021;2021:9944589. https://doi.org/10.1155/2021/9944589.CrossRefPubMedPubMedCentral

84.

Wernig G, Chen SY, Cui L, et al. Unifying mechanism for different fibrotic diseases. Proc Natl Acad Sci USA. 2017;114(18):4757–62. https://doi.org/10.1073/pnas.1621375114.CrossRefPubMedPubMedCentral

85.

Wrann CD, Rosen ED. New insights into adipocyte-specific leptin gene expression. Adipocyte. 2012;1(3):168–72. https://doi.org/10.4161/adip.20574.CrossRefPubMedPubMedCentral

86.

Wrann CD, Eguchi J, Bozec A, et al. FOSL2 promotes leptin gene expression in human and mouse adipocytes. J Clin Invest. 2012;122(3):1010–21. https://doi.org/10.1172/JCI58431.CrossRefPubMedPubMedCentral

87.

Li J, Li S, Hu Y, et al. The expression level of mRNA, protein, and DNA methylation status of FOSL2 of Uyghur in XinJiang in type 2 diabetes. J Diabetes Res. 2016;2016:5957404. https://doi.org/10.1155/2016/5957404.CrossRefPubMedPubMedCentral

88.

Liang Y, Yuan W, Zhu W, et al. Macrophage migration inhibitory factor promotes expression of GLUT4 glucose transporter through MEF2 and Zac1 in cardiomyocytes. Metabolism. 2015;64(12):1682–93. https://doi.org/10.1016/j.metabol.2015.09.007.CrossRefPubMed

89.

Wang J, Tong C, Yan X, et al. Limiting cardiac ischemic injury by pharmacological augmentation of macrophage migration inhibitory factor-AMP-activated protein kinase signal transduction. Circulation. 2013;128(3):225–36. https://doi.org/10.1161/CIRCULATIONAHA.112.000862.CrossRefPubMedPubMedCentral

90.

Zhang D, Golubkov VS, Han W, et al. Identification of Annexin A4 as a hepatopancreas factor involved in liver cell survival. Dev Biol. 2014;395(1):96–110. https://doi.org/10.1016/j.ydbio.2014.08.025.CrossRefPubMedPubMedCentral

91.

Monkemann H, De Vriese AS, Blom HJ, et al. Early molecular events in the development of the diabetic cardiomyopathy. Amino Acids. 2002;23(1-3):331–6. https://doi.org/10.1007/s00726-001-0146-y.CrossRefPubMed

92.

Kitada K, Nakano D, Ohsaki H, et al. Hyperglycemia causes cellular senescence via a SGLT2- and p21-dependent pathway in proximal tubules in the early stage of diabetic nephropathy. J Diabetes Complications. 2014;28(5):604–11. https://doi.org/10.1016/j.jdiacomp.2014.05.010.CrossRefPubMedPubMedCentral

93.

Almeida De Oliveira A, Faustino J, Pedrosa Nunes KJH. Abstract P190: transcriptomic data analysis reveals sex-related differences in the interplay between toll-like receptor 4 and heat-shock protein 70 in the aorta of type 2 diabetic donors. Hypertension. 2019;74(Suppl_1):AP190-AP. https://doi.org/10.1161/hyp.74.suppl_1.P190.CrossRef

94.

Fiorese CJ, Schulz AM, Lin YF, et al. The transcription factor ATF5 mediates a mammalian mitochondrial UPR. Curr Biol. 2016;26(15):2037–43. https://doi.org/10.1016/j.cub.2016.06.002.CrossRefPubMedPubMedCentral

95.

Juliana CA, Yang J, Rozo AV, et al. ATF5 regulates beta-cell survival during stress. Proc Natl Acad Sci USA. 2017;114(6):1341–6. https://doi.org/10.1073/pnas.1620705114.CrossRefPubMedPubMedCentral

96.

Pei-Yuan Z, Yu-Wei L, Xiang-Nan Z, et al. Overexpression of Axl reverses endothelial cells dysfunction in high glucose and hypoxia. J Cell Biochem. 2019;120(7):11831–41. https://doi.org/10.1002/jcb.28462.CrossRefPubMed

97.

Wu W, Xu H, Meng Z, et al. Axl is essential for in-vitro angiogenesis induced by vitreous from patients with proliferative diabetic retinopathy. Front Med (Lausanne). 2021;8:787150. https://doi.org/10.3389/fmed.2021.787150.CrossRefPubMedPubMedCentral

98.

Su SC, Chiang CF, Hsieh CH, et al. Growth arrest-specific 6 modulates adiponectin expression and insulin resistance in adipose tissue. J Diabetes Investig. 2021;12(4):485–92. https://doi.org/10.1111/jdi.13412.CrossRefPubMed

99.

Arai H, Nagai K, Doi T. Role of growth arrest-specific gene 6 in diabetic nephropathy. Vitam Horm. 2008;78:375–92. https://doi.org/10.1016/S0083-6729(07)00015-5.CrossRefPubMed

100.

Ljubimov AV, Burgeson RE, Butkowski RJ, et al. Basement membrane abnormalities in human eyes with diabetic retinopathy. J Histochem Cytochem. 1996;44(12):1469–79. https://doi.org/10.1177/44.12.8985139.CrossRefPubMed

101.

Burlina S, Banfi C, Brioschi M, et al. Is the placental proteome impaired in well-controlled gestational diabetes? J Mass Spectrom. 2019;54(4):359–65. https://doi.org/10.1002/jms.4336.CrossRefPubMed

102.

Zhang Y, Cui L, Guan G, et al. Matrine suppresses cardiac fibrosis by inhibiting the TGF-beta/Smad pathway in experimental diabetic cardiomyopathy. Mol Med Rep. 2018;17(1):1775–81. https://doi.org/10.3892/mmr.2017.8054.CrossRefPubMed

103.

Malek V, Gaikwad AB. Telmisartan and thiorphan combination treatment attenuates fibrosis and apoptosis in preventing diabetic cardiomyopathy. Cardiovasc Res. 2019;115(2):373–84. https://doi.org/10.1093/cvr/cvy226.CrossRefPubMed

104.

Che H, Wang Y, Li Y, et al. Inhibition of microRNA-150-5p alleviates cardiac inflammation and fibrosis via targeting Smad7 in high glucose-treated cardiac fibroblasts. J Cell Physiol. 2020;235(11):7769–79. https://doi.org/10.1002/jcp.29386.CrossRefPubMed

105.

Frangogiannis NG. Cardiac fibrosis. Cardiovasc Res. 2021;117(6):1450–88. https://doi.org/10.1093/cvr/cvaa324CrossRefPubMed

106.

Wang Y, Yu K, Zhao C, et al. Follistatin attenuates myocardial fibrosis in diabetic cardiomyopathy via the TGF-beta-Smad3 pathway. Front Pharmacol. 2021;12:683335. https://doi.org/10.3389/fphar.2021.683335.CrossRefPubMedPubMedCentral

107.

Dong L, Li JC, Hu ZJ, et al. Deletion of Smad3 protects against diabetic myocardiopathy in db/db mice. J Cell Mol Med. 2021;25(10):4860–9. https://doi.org/10.1111/jcmm.16464.CrossRefPubMedPubMedCentral

108.

Panchapakesan U, Pegg K, Gross S, et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy? PLoS One. 2013;8(2):e54442. https://doi.org/10.1371/journal.pone.0054442.CrossRefPubMedPubMedCentral

109.

Xu H, Qing T, Shen Y, et al. RNA-seq analyses the effect of high-salt diet in hypertension. Gene. 2018;677:245–50. https://doi.org/10.1016/j.gene.2018.07.069.CrossRefPubMed

110.

Gallini R, Lindblom P, Bondjers C, Betsholtz C, Andrae J. PDGF-A and PDGF-B induces cardiac fibrosis in transgenic mice. Exp Cell Res. 2016;349(2):282–90. https://doi.org/10.1016/j.yexcr.2016.10.022.CrossRefPubMed

111.

Ye Y, Jia X, Bajaj M, Birnbaum Y. Dapagliflozin attenuates Na(+)/H(+) exchanger-1 in cardiofibroblasts via AMPK activation. Cardiovasc Drugs Ther. 2018;32(6):553–8. https://doi.org/10.1007/s10557-018-6837-3.CrossRefPubMed

Titel: Effects of Dapagliflozin on Myocardial Gene Expression in BTBR Mice with Type 2 Diabetes
verfasst von: Maria Ryaboshapkina
Regina Ye
Yumei Ye
Yochai Birnbaum
Publikationsdatum: 02.11.2023
Verlag: Springer US
Erschienen in: Cardiovascular Drugs and Therapy
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI: https://doi.org/10.1007/s10557-023-07517-1

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Effects of Dapagliflozin on Myocardial Gene Expression in BTBR Mice with Type 2 Diabetes

Abstract

Background

Methods

Results

Neu im Fachgebiet Kardiologie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Update Kardiologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Background

Methods

Results

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Kardiologie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Update Kardiologie